Metagenomi Therapeutics, Inc.
MGX · XNASCIK 1785279fmd_1JKWDF0N1PAY4GYZ4JSTHRFB75Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2023 to Sep 30, 2026, 15 periods
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Total revenues | 45 | 52 | 25 |
| Research and development | 94 | 109 | 94 |
| Total operating expenses | 123 | 141 | 121 |
| Operating income | (78) | (89) | (96) |
| Interest and investment income | 15 | 15 | 9 |
| Other non-operating income (expense) | 18 | 5 | 8 |
| Income before taxes | (60) | (84) | (88) |
| Income tax expense | 8 | (6) | (0) |
| Net income from continuing operations | (68) | (78) | (88) |
| Net income | (68) | (78) | (88) |
| Net income to common shareholders | (68) | (78) | (88) |